Guoping Yang - Publications, H-index & Citations

Guoping Yang

central south university

32H指数

303论文数

4.4K被引数

收录论文 124

发表时间

Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial BGM0504，一种双重GLP-1/GIP受体激动剂，在中国超重或肥胖且无糖尿病成人中的有效性、安全性和药代动力学：一项Ⅱ期多中心、随机、双盲、安慰剂对照试验

DIABETES OBESITY & METABOLISM

IF5.7

2026-09-18

PREAI

Linong Ji; Guoping Yang; Yangqing Huang; Haifeng Ding; Daosheng Xie; Xiaohui Jiang; Xuemei Yuan; Zhao Cao; Zou Chan; Haibin Zhang; Jiandong Yuan

Population pharmacokinetic/pharmacodynamic modeling of NH600001 reveals age-related differences in sedation response and supports individualized dosing in elderly patients NH600001的群体药代动力学/药效动力学模型揭示镇静反应的年龄相关性差异，并支持老年患者的个体化给药

Expert Opinion on Drug Metabolism & Toxicology

IF3.4

2026-09-17

PREAI

Ya-Jie Cao; Yun Kuang; Qi Gao; Kun-Hong Deng; Qi Pei; Ya-Xin Liu; Guo-Ping Yang

A certifiable evidence-chain digital platform supporting decentralized clinical trials: architecture and real-world evaluation 一种支持去中心化临床试验的可认证证据链数字平台：架构与真实世界评估

npj Digital Medicine

IF15.1

2026-09-17

OAAI

Yuxia Xiang; Yun Kuang; Jie Huang; Yanan Liu; Jiao Tang; Chan Zeng; Cong Liu; Ying Xu; Yichang Shan; Zhijun Huang; Chengxian Guo; Guoping Yang

Machine Learning Enables Rapid Prediction of Acid-Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling 机器学习实现酸抑制剂药物相互作用的快速预测：PBPK建模的简化补充

CPT-Pharmacometrics & Systems Pharmacology

IF3

2026-09-15

OAAI

Yuanfang Qin; Lehua Yu; Tao Chen; Yonghui Zuo; Hongyun Wang; Guoping Yang; Qi Pei

Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study GLP-1/GIP/GCG受体激动剂UBT251注射剂的安全性、药代动力学和药效学研究：一项随机、安慰剂对照的1a/1b期研究

DIABETES OBESITY & METABOLISM

IF5.7

2026-09-09

PREAI

Guo-ping Yang; Ya-xin Liu; Jin-lian Xie; Shan Zeng; Jing Xiong; Wei Ling; Hai-yan Zhang; Tao Su; Yu-xiu Xu; Liang Huang; Thomas Holst-Hansen; Sofie Bay; Hui-ru Yan; Jie Huang; Ping Jin

First-in-Human Phase I Trial of HRS-2129, a Selective Nav1.8 Inhibitor: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects HRS-2129（一种选择性Nav1.8抑制剂）首次人体I期临床试验：健康受试者的安全性、耐受性、药代动力学和药效学研究

Drug Design Development and Therapy

IF5.1

2026-09-03

OAAI

Jie Huang; Qian Wu; Saiying Wang; Jinlian Xie; Kunhong Deng; Shuang Yang; Xiaoyan Yang; Chuanpin Chen; Guoping Yang

A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes 微剂量联合用药和群体药代动力学研究提示2型糖尿病患者中CYP3A和P-gp活性可能降低

Frontiers in Pharmacology

IF4.8

2026-08-28

OAAI

YL Yafen Li †; JY Jin Yang †; EZ Enda Zhou; KG Kuo Geng; ZL Zihan Lei; XY Xueting Yao; FF Feifei Feng; YJ Yuyan Jin; WK Weijie Kong; YH Yiyi Hu; HL Hao Liang; HL Haiyan Li; GY Guo-Ping Yang; TH Tianpei Hong; DL Dongyang Liu

A phase I clinical study of the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-2106, an anti-CD40 antibody, following single intravenous or subcutaneous administration in healthy participants SHR-2106（一种抗CD40抗体）在健康受试者中单次静脉或皮下给药后的安全性、耐受性、药代动力学和药效学的I期临床研究

European Journal of Pharmacology

IF4.7

2026-08-26

PREAI

Jie Huang; Qiang-da Huang; Jin-lian Xie; Qian Wu; Kun-hong Deng; Shuang Yang; Xiao-yan Yang; Ying Wang; Ying Zhu; Qiuna Du; Chuanpin Chen; Guo-ping Yang

Integrating Clinical Evidence with PBPK Modeling to Assess PPI-Clopidogrel-CYP2C19 Interactions in Chinese ACS Patients 整合临床证据与PBPK建模以评估中国ACS患者中PPI-氯吡格雷-CYP2C19的相互作用

Pharmaceutical Research

IF4.3

2026-07-21

PREAI

Ya-xin Liu; Yun Kuang; Jun-long Ma; Jin-long Liu; Nuo Xu; Qi Pei; Li-ying Gong; Guo-ping Yang

Retrieval-augmented generation for medication safety: A case study using drug package inserts 检索增强生成技术在用药安全中的应用：一项基于药品说明书的研究

International Journal of Medical Informatics

IF4.1

2026-07-07

PREAI

Yuanyuan Sun; Wei Wang; Wanqiu Cheng; Ronghui Li; Xiang Liu; Qi Pei; Jintao Tang; Guoping Yang

High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study 住院老年患者肝毒性药物相互作用的高通量信号检测：一项基于NLP的药物警戒研究

Annals of Medicine

IF4.3

2026-06-17

OAAI

Junlong Ma; Heng Chen; Chengxian Guo; Gefei He; Guoping Yang

A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity I期、随机、双盲、安慰剂对照试验，评估KN069（一种GLP-1R激动剂和GIPR拮抗剂）在超重或肥胖男性成人中的安全性、耐受性、药代动力学和药效动力学

diabetes, obesity and metabolism

IF0

2026-04-20

PREAI

Jinlian Xie; Jie Huang; Qian Wu; Kunhong Deng; Shuang Yang; Sibo Yang; Shuting Wu; Xiaoyan Yang; Wenqiao Huang; Yanrong Dong; Jing Li; Guoping Yang; Chengxian Guo

The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities NLRP3炎性小体：激活机制、调控机制及治疗机会

MedComm

IF10.7

2026-03-05

OAAI

Chan Zou; Shilong Jiang; Hui Li; Kai Zhao; Dongshen Cao; Guoping Yang

Prediction of vancomycin exposure in patients with central nervous system infections using physiologically based pharmacokinetic modeling

Journal of Pharmaceutical Sciences

IF3.8

2026-02-05

PREAI

Ya-xin Liu; Yun Kuang; Jin-long Liu; Qi Pei; Li-ying Gong; Guo-ping Yang

Safety, Pharmacokinetics, and Sex Hormone Suppression of LY01021 versus Relugolix: A Single- and Multiple-Dose Escalation Study

European Journal of Pharmacology

IF4.7

2026-02-05

PREAI

Yafen Li; Hongyi Tan; Jinlian Xie; Kunhong Deng; Qian Wu; Shuang Yang; Xiaoyan Yang; Jinlei Li; Xiang-Lei Jia; Jin Tong; Jie Huang; Guo-Ping Yang

Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI/FXIa dual-domain antibody, following single ascending doses in healthy chinese subjects 安全性、耐受性、药代动力学和药效动力学研究：评估单次递增剂量给药后KN060（一种人源化抗FXI/FXIa双域抗体）在健康中国受试者中的表现

Research and Practice in Thrombosis and Haemostasis

IF3.4

2025-12-29

OAAI

Jie Huang; Jinlong Liu; Yaxin Liu; Yichen Cao; Wei Sun; Yanrong Dong; Yuwei Li; Jing Li; Qian Wu; Xiaoyan Yang; Shuang Yang; Chuanpin Chen; Guoping Yang

Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects 纳库巴坦（OP0595）静脉输注后的药代动力学、安全性和耐受性：一项在健康中国男性受试者中进行的随机、双盲、安慰剂对照的I期临床试验

Clinical and Experimental Medicine

IF3.5

2025-12-02

OAAI

Hui Qiu; Tingting Wu; Lei Diao; Nianda Yu; Hong Chen; Xi Peng; Jie Huang; Jinlian Xie; Qian Wu; Shuang Yang; Xiaoyan Yang; Long Zeng; Qi Pei; Chengxian Guo; Guoping Yang

A biocompatible tea polyphenol nanoplatform for efficient cytosolic delivery of protein therapeutics 一种生物相容性茶多酚纳米平台，用于高效胞质递送蛋白质治疗药物

Journal of Controlled Release

IF11.5

2025-10-25

PREAI

Hui Wang; Cui Tang; Hanfeng Zhang; Lina Guo; Chan Zou; Shengting Zhang; Jinlong Liu; Qianping Huang; Yujun Liu; Wenhu Zhou; Guoping Yang; Xiang Gao

Safety, tolerability, and pharmacokinetics of 4-fluoroetomidate (NH600001) in healthy subjects: a first-in-human, randomised, controlled, phase I study 4-氟乙妥咪酯（NH600001）在健康受试者中的安全性、耐受性和药代动力学：一项首次人体、随机、对照、I期研究

European Journal of Pharmaceutical Sciences

IF4.7

2025-10-10

OAAI

Yuanyuan Sun; Jie Huang; Kaiming Duan; Yaqi Lin; Qian Wu; Jinlian Xie; Can Guo; Yajie Cao; Ling Ye; Shuang Yang; Saiying Wang; Guo-Ping Yang

Efficacy, pharmacokinetics, and safety of nebulized HL231 inhalation solution in patients with chronic obstructive pulmonary disease: a randomized trial 雾化HL231吸入溶液在慢性阻塞性肺疾病患者中的疗效、药代动力学和安全性：一项随机试验

JOURNAL OF THORACIC DISEASE

IF1.9

2025-10-01

PREAI

Hu, Qingyuan; Zhao, Li; Yang, Guoping; Wen, Fuqiang; Xie, Lihua; Xiao, Zuke; Chen, Feng; He, Qing; Bian, Tao; Xiong, Hao; Li, Fangqiong; Yue, Yun; Li, Yaming; Luo, Lin; Luo, Zhu

研究方向